Santa Clara, CA, United States of America

Michael Nathaniel Alonso

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • Redwood City, CA (US) (2022)
  • Santa Clara, CA (US) (2020 - 2023)

Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Michael Nathaniel Alonso: Innovator in Cancer Treatment

Introduction

Michael Nathaniel Alonso, an inventive mind located in Santa Clara, California, has made significant contributions to the field of immunotherapy through his numerous patents. With a total of four patents to his name, his work focuses on developing novel antibody conjugates aimed at treating cancer effectively.

Latest Patents

Among his most recent inventions, Alonso has developed innovative antibody adjuvant conjugates. This invention offers an immunoconjugate that includes an antibody construct featuring an antigen binding domain and an Fc domain, combined with an adjuvant moiety linked covalently to the antibody. The design enhances the treatment methods for cancer using these immunoconjugates. Additionally, he has created immunoconjugates targeting HER2. This specific formulation includes an antibody construct that binds HER2, providing promising compositions and methods to treat cancer effectively.

Career Highlights

Throughout his career, Alonso has been associated with esteemed organizations like Bolt Biotherapeutics, Inc. and Leland Stanford Junior University. His tenure at these institutions has paved the way for his innovative research, contributing significantly to advancements in cancer treatment.

Collaborations

Michael Nathaniel Alonso has collaborated with notable colleagues such as Edgar George Engleman and Shelley Erin Ackerman. These partnerships have played a vital role in his research endeavors, fostering a collaborative environment for developing groundbreaking therapeutic options.

Conclusion

Michael Nathaniel Alonso continues to be a pivotal player in the field of cancer research and immunotherapy. With his impressive portfolio of patents and productive collaborations, he is poised to make further advancements that could transform cancer treatment methods. His work exemplifies the spirit of innovation and commitment to improving patient outcomes in the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…